UCB will ad­vance its an­ti-tau an­ti­body for Alzheimer’s dis­ease so­lo af­ter Roche and Genen­tech walked away from the as­set known as bepranemab.
UCB granted Roche and its biotech unit Genentech an exclusive worldwide license to bepranemab, then called UCB0107, in 2020 as part of a deal worth around $2 billion in milestones. The agreement ...
--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline one-year results from the open-label, single-arm Phase IV ELEVATUM study ...
As Election Day 2024 gets closer, STAT’s First Opinion asked executives from leading biotech and pharmaceutical companies to reflect on how their industry is being portrayed in the presidential ...
This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox. Good morning! For those who ...
Genentech’s parent company Roche said the $850m deal lines up with its plan to focus on three therapeutic areas including oncology. RHHBY has strengthened its pipeline with an agreement to acquire ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented positive 2-year data from the ongoing RAINBOWFISH study at the 29th ...
The Rainbowfish trial (NCT03779334), run by the Roche subsidiary Genentech, enrolled babies aged from birth to six weeks who had not yet shown symptoms of SMA. After two years, all 26 children were ...
Roche Group unit Genentech said that the Food and Drug Administration approved Itovebi for treating certain breast cancer. The approval is for Itovebi in combination with palbociclib and ...
A roundup of the most newsworthy financial press releases from PR Newswire this week, including ADP's National Employment Report, Aetna's 2025 Medicare plans and OwlTing's collab with Visa.
You are one of 7.5 million annual visitors to OpenSecrets. If you each donated just $1 a year, we'd never worry about funding again.